Filing Details
- Accession Number:
- 0001209191-20-034544
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-06-04 18:40:15
- Reporting Period:
- 2020-06-02
- Accepted Time:
- 2020-06-04 18:40:15
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1080709 | Arena Pharmaceuticals Inc | ARNA | Pharmaceutical Preparations (2834) | 232908305 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1657494 | Vincent Aurentz | C/O Arena Pharmaceuticals, Inc. 6154 Nancy Ridge Drive San Diego CA 92121 | Executive Vp And Cbo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-06-02 | 10,000 | $17.10 | 10,000 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2020-06-02 | 10,000 | $14.60 | 20,000 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2020-06-02 | 5,000 | $35.60 | 25,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-06-02 | 25,000 | $65.00 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2020-06-02 | 10,000 | $0.00 | 10,000 | $17.10 |
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2020-06-02 | 10,000 | $0.00 | 10,000 | $14.60 |
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2020-06-02 | 5,000 | $0.00 | 5,000 | $35.60 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 45,000 | 2023-08-15 | No | 4 | M | Direct | |
| 79,500 | 2024-02-13 | No | 4 | M | Direct | |
| 95,000 | 2025-01-19 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.00 to $65.01, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4.
- The options vest over four years, with 25% of the shares subject to the option vesting on August 15, 2017, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.
- The options vest over four years, with 25% of the shares subject to the option vesting on February 13, 2018, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.
- The options vest over four years, with 25% of the shares subject to the option vesting on January 19, 2019, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.
Billionaire Hedge Funds
